Published in J Immunother Cancer on August 18, 2015
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | NCT02085070
Treatment of Advanced Melanoma With MK-3475 and Peginterferon | NCT02112032
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-labeled Pembrolizumab. J Nucl Med (2016) 0.87
Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report. Respir Med Case Rep (2017) 0.80
Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol (2017) 0.76
Monitoring of the Immune Dysfunction in Cancer Patients. Vaccines (Basel) (2016) 0.75
PD-L1 expressing circulating tumour cells in head and neck cancers. BMC Cancer (2017) 0.75
A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. Onco Targets Ther (2016) 0.75
A 76 year old male with an unusual presentation of merkel cell carcinoma. Int J Surg Case Rep (2016) 0.75
Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. Onco Targets Ther (2016) 0.75
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res (2016) 0.75
Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 2.97
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol (2015) 1.25
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer (2015) 1.24
Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol (2014) 1.23
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother (2015) 0.92
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer (2015) 0.88